Forschungsprojekte Anthropogene Spurenstoffe - DWA
Forschungsprojekte Anthropogene Spurenstoffe - DWA
Forschungsprojekte Anthropogene Spurenstoffe - DWA
Erfolgreiche ePaper selbst erstellen
Machen Sie aus Ihren PDF Publikationen ein blätterbares Flipbook mit unserer einzigartigen Google optimierten e-Paper Software.
<strong>Forschungsprojekte</strong> zu anthropogenen <strong>Spurenstoffe</strong>n im Wasserkreislauf<br />
75 Titel<br />
Kurztitel<br />
Verbundpartner/<br />
Projektnehmer<br />
Kontakt<br />
Projektträger/<br />
Finanzierung<br />
Laufzeit<br />
Identification and reduction of environmental risks caused by the use of<br />
human pharmaceuticals<br />
MistraPharma<br />
Royal Institute of Technology (KTH), Department of Philosophy<br />
Uppsala University, Evolutionary Biology Center (EBC)<br />
Department of Physiology and Developmental Biology (IFU)<br />
Umeå University, Department of Chemistry<br />
Lund University, Department of Chemical Engineering<br />
Stockholm University, Department of Applied Environmental Science<br />
The Sahlgrenska Academy at Göteborg University, Institute of<br />
Neuroscience and Physiology<br />
Christina Rudén (Programme director)<br />
MistraPharma<br />
Royal Institute of Technology (KTH)<br />
Department of Philosophy<br />
Teknikringen 78B<br />
S-100 44 Stockholm<br />
Schwedische Stiftung für strategische Umweltforschung, Mistra<br />
Kurzfassung<br />
Identification of pharmaceuticals of environmental concern<br />
MistraPharma will contribute to identifying the active pharmaceutical ingredients on the<br />
Swedish market most likely to cause adverse effects in the aquatic environment. The<br />
programme will also generate data on which molecular structure elements that are important<br />
for biodegradability of pharmaceutical compounds.<br />
Recommendations to improve wastewater treatment technologies<br />
MistraPharma will identify and develop wastewater treatment technologies that will help<br />
improve the elimination of high-risk pharmaceuticals from waste water treatment plants. Any<br />
recommendations to improve waste water treatment will be based on an integrated analysis<br />
taking into account what is environmentally motivated, technically feasible and economically<br />
realistic.<br />
Improved risk identification strategies<br />
MistraPharma will develop new tools for detecting environmental effects of human<br />
pharmaceuticals based on the compounds´ expected pharmacological mechanisms or using<br />
explorative methods covering a broad range of biological interactions. Based on these<br />
methods MistraPharma will propose new approaches to ecotoxicological testing of<br />
pharmaceuticals.<br />
Stakeholder communication<br />
MistraPharma will ensure that the stakeholders, such as the pharmaceutical industry,<br />
national, regional and local authorities, waste water treatment plants and, health care, are<br />
actively informed about and given access to the new knowledge and expertise that will<br />
108
Change language